Close Menu

NEW YORK – BGI said last week that its nucleic acid detection kit for bloodstream infection pathogens has received the CE mark.

The kit, developed by BGI Patho-Genesis Pharmaceutical Technology, a holding subsidiary of BGI Genomics, uses combinatorial probe-anchor synthesis technology to prepare libraries for metagenomic sequencing to detect pathogens that cause bloodstream infections. It is designed to construct a sequencing library directly from clinical samples.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.